Investigating how monoclonal antibodies behave in solution to improve drug development
Assessment of self-association of monoclonal antibody molecules by analysis of the protein layer detected at the proximity of a solid surface
This study is looking at how certain antibodies behave in order to make better treatments for conditions like rheumatoid arthritis and asthma, helping to ensure that the most effective options are developed for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10849829 on NIH RePORTER |
What this research studies
This research focuses on understanding the self-association of monoclonal antibodies (mAbs) to improve their manufacturability and stability for treating conditions like rheumatoid arthritis and asthma. By developing a new method to measure how these proteins interact in solution, the research aims to predict their behavior and identify potential issues early in the drug development process. This could lead to more effective mAb therapies by ensuring that only the most promising candidates are advanced in development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from conditions like rheumatoid arthritis, asthma, or atopic dermatitis who may benefit from improved monoclonal antibody therapies.
Not a fit: Patients who do not have conditions treated by monoclonal antibodies or those who are not eligible for mAb therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and stable monoclonal antibody treatments for various diseases.
How similar studies have performed: Other research has shown promise in improving monoclonal antibody therapies through similar approaches, indicating potential for success in this area.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Nejadnik, Reza — University of Iowa
- Study coordinator: Nejadnik, Reza
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.